

Author's Accepted Manuscript

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST v1.1-defined disease progression in clinical trials

Dickran Kazandjian, Patricia Keegan, Daniel L Suzman, Richard Pazdur, Gideon M Blumenthal



PII: S0093-7754(16)30144-0
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2017.01.001>
Reference: YSONC51984

To appear in: *Seminars in Oncology*

Cite this article as: Dickran Kazandjian, Patricia Keegan, Daniel L Suzman, Richard Pazdur and Gideon M Blumenthal, Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST v1.1-defined disease progression in clinical trials, *Seminars in Oncology*, <http://dx.doi.org/10.1053/j.seminoncol.2017.01.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title Page

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST v1.1-defined disease progression in clinical trials

Authors: Dickran Kazandjian MD^{1,2*}, Patricia Keegan MD¹, Daniel L Suzman MD¹, Richard Pazdur MD¹, and Gideon M Blumenthal MD¹

Affiliations: Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA; Myeloma program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., Bethesda, Maryland, 20854, USA

Corresponding Author: Dickran Kazandjian, MD, Food and Drug Administration, White Oak Campus, 10903 New Hampshire Avenue, Building 22, Room 2320, Silver Spring, Maryland 20993, USA. Telephone: 240-402-5272; email: Dickran.kazandjian@fda.hhs.gov

Disclaimers: None

Research Support: None

Key Words: treatment beyond progression, Non-Small-Cell Lung Carcinoma, PD-1 Inhibitor, Immunotherapy

Download English Version:

<https://daneshyari.com/en/article/5530229>

Download Persian Version:

<https://daneshyari.com/article/5530229>

[Daneshyari.com](https://daneshyari.com)